JPH08119875A - Rhinitis treating agent - Google Patents

Abstract

PURPOSE: To obtain a nasal drop for preventing and treating rhinitis, containing α-linolenic acid-based oil and fat. CONSTITUTION: This rhinitis treating agent contain one component or plural components in α-linolenic acid-based oil and fat containing a highly unsaturated fatty acid of α-linolenic acid, eicosapentaenoic acid, docosahexaenoic acid and these derivatives. A vegetable oil such as perilla oil, linseed oil and egoma oil rich in α-linolenic acid, fish oil of horse mackerel, sardine, Pacific saury, etc., rich in eicosapentaenoic acid and docosahexaenoic acid or oil and fat of sea grasses can be used as origin of the α-linolenic acid-based oil and fat. An antioxidant such as vitamin E, vitamin C, carotene or tea catechins can be blended in addition to α-linolenic acid-based oil and fat. Though the nasal drop is preferably dropped, jetted or sprayed into nose cavity, the drop may be applied to the surface of nasal hole. α-Linolenic acid-based metabolism suppresses metabolism of linolenic acid and relieves allergic symptom.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a nasal spray for preventing and treating rhinitis, which comprises .alpha.-linolenic acid oil as a main component.

[0002]

2. Description of the Related Art In recent years, allergic rhinitis, which is caused by hypersensitivity of nasal mucosa to specific substances such as air pollution such as air pollution, hay fever, mites and molds, house dust, dust, dust, etc., has increased rapidly. . The characteristic of this allergic rhinitis is characterized by recurrent sneezing, aqueous nasal discharge, and nasal obstruction that appear with paroxysm.

Inhalable allergens are dissolved in the mucus layer on the surface of the nasal mucosa, dissolved in the epithelium and absorbed. This dissolved antigenic substance reacts with the IgE antibody on the surface of mast cells gathered in the mucosal epithelium, and histamine, leukotriene,
Chemical mediators such as PAF (platelet activating factor) are released. These induce various allergic symptoms such as sneezing, nasal discharge, and nasal congestion.

As therapeutic agents for allergic rhinitis, antihistamine agents, antiallergic agents, topical steroid agents, and topical anticholinergic agents are used depending on the symptoms. However, the use of these drugs cannot improve long-term use because they temporarily improve rhinitis or cause side effects such as sleepiness, liver damage, cystitis, and dryness.

As a treatment for nasal allergy, a treatment method centering on desensitization of mites, molds, house dust, and cedar pollen should be prioritized. This desensitization treatment takes a long time of half a year to one year until it shows an effect. It takes a long time and requires considerable patience for the patient.

[0006] Rhinitis refers to inflammation occurring in the mucous membrane of the nose, and includes allergic rhinitis as well as acute rhinitis and chronic rhinitis.

Since rhinitis has congestion in the nasal mucosa, it is effective to administer nasal drops. Nasal drops include vasoconstrictors such as Coaltaidine (Pfizer), Cinaclin (Otsuka Pharmaceutical), Navel (Chugai Pharmaceutical), and Talk (Tanabe Pharmaceutical).

[0008] When these vasoconstrictors are used, the blood vessels of the nasal mucosa are contracted so that congestion is removed and the substance is refreshed, but if it is continuously used, the effect is weakened, and therefore it cannot be used frequently.

[0009]

Conventionally used drugs cause side effects such as sleepiness, liver damage, cystitis, and dryness, and various nasal drops used as vasoconstrictors are also addictive. , It is difficult to use for a long time.

The present invention solves these problems and provides a remedy for rhinitis, which has symptoms such as sneezing, nasal discharge and nasal congestion.

[0011]

Means for Solving the Problems In order to solve the above problems, a rhinitis containing α-linolenic acid-based fats and oils as a main component and using α-linolenic acid-based fats and oils as a main component and vegetable oil, fish oil, seaweed, etc. It relates to preventive and therapeutic nasal drops.

When allergens such as mites, molds, house dust, and cedar pollen enter the body, an excessive allergic reaction occurs to protect the body from allergens, resulting in an allergic reaction, which is a trigger for allergic symptoms. Chemical mediators such as histamine, leukotriene and PAF are produced from fatty acids in the body.

This fatty acid metabolism includes important unsaturated fatty acid metabolism of linoleic acid (n6) series and α-linolenic acid (n3) series.

The two have different metabolic pathways, and the linoleic acid series traces the metabolic pathway of linoleic acid → γ-linolenic acid → aragidonic acid, while the α-linolenic acid series is α-linolenic acid → eicosapentaenoic acid (EPA). ) → It is known to be metabolized to another fatty acid of docosahexaenoic acid (DHA).

Leukotriene can be produced from either linoleic acid or α-linolenic acid, but leukotriene (5) produced from α-linolenic acid series has extremely weak allergic activity, while leukotriene produced from aragido acid of linoleic acid series. (4) causes strong allergic symptoms.

Α-Linolenic acid, EPA, DHA, etc. α-
The linolenic acid series substances suppress the metabolism of the linoleic acid series and alleviate allergic symptoms.

The present inventor pays attention to the antiallergic action of α-linolenic acid-based fats and oils, which contains α-linolenic acid-based fats and oils as a main component in order to exert immediate effect on the treatment of rhinitis, and prevents and treats rhinitis without side effects. This led to the invention of nasal drops.

The α-linolenic acid oil used in the present invention is α
-A polyunsaturated fatty acid such as linolenic acid, EPA, DAH, and derivatives thereof are included. These components can be used alone or in combination of two or more.

The origin of α-linolenic acid-based oils and fats is vegetable oils such as perilla oil, linseed oil, and sesame oil, which have a high α-linolenic acid content, fish oils such as tuna, sardines, saury and the like, which contain a large amount of EPA and DHA, oils and fats of seaweeds, etc. Can be used alone or in combination.

Perilla oil is extracted from perilla seeds, sesame oil is extracted from perilla seeds of the Labiatae family, linseed oil is extracted from flax seeds, and these vegetable oils contain α-linolenic acid.
Abundantly contained in the range of 60% to 60%.

Antioxidants such as vitamin E, vitamin C, carotene, and tea catechins can be added to the therapeutic composition using α-linolenic acid-based fats and oils.

The vegetable oils, fish oils and seaweeds used as the origin of the α-linolenic acid-based oils and fats of the present invention can be inexpensively used and produced, and have no side effects because they are taken as daily food.

Incidentally, olive oil, rapeseed oil, sesame oil, soybean oil, sunflower oil and safflower oil, which are rich in saturated fatty acids and monounsaturated fatty acids, are not suitable as the main component of the present invention.

The nasal drops of the present invention are preferably dropped, sprayed or sprayed in the nasal cavity, but may be applied to the surface of the nostrils. When using nasal drops, it is possible to further enhance the therapeutic effect by performing nasal washing and vapor inhalation in advance. Nose tip and vapor inhalation are not limited to the present invention.

[0025]

The present invention utilizes the anti-allergic effect of α-linolenic acid-based fats and oils, and by using a nasal drop containing α-linolenic acid-based fats and oils as a main component, there are no side effects and rhinitis can be rapidly prevented or prevented. Can be treated.

[0026]

Example A nasal drop containing 100 g of perilla oil and 0.1 g of vitamin E, 0.1 g of vitamin C and 0.05 g of tea catechin was prepared. Five subjects with rhinitis are washed several times in advance with saline inhaled into the nostrils several times in advance, and then 2-3 drops of nasal drops are placed in each nostril. Prone for 1-2 minutes until it penetrates the nasal mucosa. This was tested three times in the morning, afternoon and before going to sleep. As a result of administering nasal drops to patients 1 (nasal discharge), patient 2 (nasal discharge), patient 3 (nasal discharge), patient 4 (nasal congestion), patient 5 (nasal congestion), rhinorrhea was administered from the next day. His nasal obstruction subsided, and there was no discomfort found in conventional nasal drops of vasoconstrictor, showing immediate effect.

[0027]

As described above, according to the present invention, nasal drops containing α-linolenic acid-based fats and oils as the main component are used without using conventional chemical drugs that have strong side effects and are addictive. Can promptly prevent or treat rhinitis.

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification code Internal reference number FI Technical display area A61K 35/78 ABF Q 8217-4C 35/80 Z 8217-4C

Claims (2)

[Claims] 1. A nasal drop for preventing and treating rhinitis, which comprises an α-linolenic acid-based oil as a main component. 2. The origin of α-linolenic acid-based oils and fats is vegetable oil,
The method according to claim 1, wherein fish oil or seaweed is used.